Can-Fite BioPharma Ltd.'s CEO Pnina Fishman Interviewed by The Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - Mar 5, 2015) - The target is a single receptor found only on abnormal cells -- cancer cells and cells responsible for inflammatory diseases such as psoriasis. The weapon is a platform technology developed by Can-Fite BioPharma Ltd. (NYSE MKT: CANF) under the guidance of Scientific Founder and CEO Pnina Fishman and her team. The company is developing an arsenal of therapies approaching the final stages of clinical trials, and in this interview with The Life Sciences Report, Fishman describes the catalysts and candidates that make Can-Fite a strong bet for investors.

The Life Sciences Report: Can-Fite BioPharma Ltd. has three candidates, two in the clinic and one preclinical, addressing cancer, inflammatory diseases and erectile dysfunction. Please describe your platform technology and how it can address these different issues.

Pnina Fishman: All our drugs target the A3 adenosine receptor, which is upregulated in pathological cells but not in normal body cells. Upon binding to inflammatory or cancer cells, our drugs induce cell death via a definitive molecular mechanism of action that has been extensively published by Can-Fite. Normal cells are refractory to the effect of the drug due to very low or no expression of the target. In glaucoma, one of our targeted therapy areas, our drug acts both as an anti-inflammatory and a neuro-protective agent by inhibiting the apoptosis of retinal ganglion cells.

If your readers would like to learn more about the mechanism of action of Can-Fite's therapies, an extensive list of published articles on our technology platform and drugs in scientific journals can be found here…

Continue reading this interview with Pnina Fishman: One Target with Multiple Shots on Goal: Can-Fite BioPharma CEO Pnina Fishman

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.

DISCLOSURE:
Can-Fite BioPharma Ltd. paid The Life Sciences Report to conduct, produce and distribute the interview. Pnina Fishman had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Pnina Fishman and not of The Life Sciences Report or its officers.

Contact Info:
Brandon Fung
Tel: [phone]
Email: Email Contact